Cargando…
Ibrutinib‐induced severe liver injury
Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a pa...
Autores principales: | Nandikolla, Amara G., Derman, Olga, Nautsch, Deborah, Liu, Qiang, Massoumi, Hatef, Venugopal, Sangeetha, Braunschweig, Ira, Janakiram, Murali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458017/ https://www.ncbi.nlm.nih.gov/pubmed/28588800 http://dx.doi.org/10.1002/ccr3.881 |
Ejemplares similares
-
Breast cancer in patients with Li–Fraumeni syndrome – a case-series study and review of literature
por: Nandikolla, Amara G, et al.
Publicado: (2017) -
JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?
por: Liu, Kenneth G., et al.
Publicado: (2016) -
Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure
por: Shah, Urvi A., et al.
Publicado: (2018) -
Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy
por: Zell, Monica, et al.
Publicado: (2016) -
Rare but Serious: Ibrutinib Induced Liver Failure
por: Kleijwegt, Fleur S., et al.
Publicado: (2019)